Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a diet-induced mouse model of nonalcoholic fatty liver disease

Molecular Nutrition and Food Research

Volumn 59, Issue 5, 2015, Pages 879-893

  Pisonero Vaquero, Sandra ^a   Martínez Ferreras, Ángel ^a   García Mediavilla, María Victoria ^a,b   Martínez Flórez, Susana ^a   Fernández, Anna ^a   Benet, Marta ^b,c   Olcoz, José Luis ^b,d   Jover, Ramiro ^b,c,e   González Gallego, Javier ^a,b   Sánchez Campos, Sonia ^a,b  

^a UNIVERSITY OF LEÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^d Gerencia Regional de Salud de Castilla y León   (Spain)

^e UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Fatty acid uptake; Lipid metabolism; NAFLD; PI3K AKT pathway; Quercetin

Indexed keywords

MUS;

CD36 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUERCETIN;

ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; LIPID METABOLISM; LIPID PEROXIDATION; MALE; METABOLISM; MOUSE; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD36; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; LIPID METABOLISM; LIPID PEROXIDATION; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUERCETIN; SIGNAL TRANSDUCTION;

EID: 84928754745     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201400913     Document Type: Article

References (67)

1. Machado, M., Cortez-Pinto, H., Non-alcoholic steatohepatitis and metabolic syndrome. Curr. Opin. Clin. Nutr. Metab. Care. 2006, 9, 637-642.
2. Tiniakos, D. G., Vos, M. B., Brunt, E. M., Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. 2010, 5, 145-171.
3. Koo, S. H., Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin. Mol. Hepatol. 2013, 19, 210-215.
4. Neuschwander-Tetri, B. A., Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH. Curr. Gastroenterol. Rep. 2010, 12, 49-56.
5. Miquilena-Colina, M. E., Lima-Cabello, E., Sánchez-Campos, S., García-Mediavilla, M. V. et al., Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 2011, 60, 1394-1402.
6. Guzmán, C., Benet, M., Pisonero-Vaquero, S., Moya, M. et al., The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARalpha and repressed by C/EBPalpha: implications in FABP1 down-regulation in nonalcoholic fatty liver disease. Biochim. Biophys. Acta 2013, 1831, 803-818.
7. Torres, D. M., Harrison, S. A., Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008, 134, 1682-1698.
8. Zeng, C. H., Zeng, P., Deng, Y. H., Shen, N. et al., The effects of curcumin derivative on experimental steatohepatitis. Zhonghua Gan Zang Bing Za Zhi 2011, 19, 454-459.
9. Salamone, F., Galvano, F., Cappello, F., Mangiameli, A. et al., Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl. Res. 2012, 159, 477-486.
10. González-Gallego, J., García-Mediavilla, M. V., Sánchez-Campos, S., Tuñón, M. J., Fruit polyphenols, immunity and inflammation. Br. J. Nutr. 2010, 104(Suppl 3), S15-S27.
11. Ying, H. Z., Liu, Y. H., Yu, B., Wang, Z. Y. et al., Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils. Food Chem. Toxicol. 2013, 52, 53-60.
12. Pisonero-Vaquero, S., García-Mediavilla, M. V., Jorquera, F., Majano, P. L. et al., Modulation of PI3K-LXRalpha-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin. Lab. Invest. 2014, 94, 262-274.
13. Li, X., Wang, R., Zhou, N., Wang, X. et al., Quercetin improves insulin resistance and hepatic lipid accumulation in a NAFLD cell model. Biomed. Rep. 2013, 1, 71-76.
14. Vidyashankar, S., Sandeep Varma, R., Patki, P. S., Quercetin ameliorate insulin resistance and up-regulates cellular antioxidants during oleic acid induced hepatic steatosis in HepG2 cells. Toxicol. In Vitro. 2013, 27, 945-953.
15. Kleiner, D. E., Brunt, E. M., VanNatta, M., Behling, C. et al., Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41, 1313-1321.
16. Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A. et al., Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010, 51, 1584-1592.
17. Sahai, A., Pan, X., Paul, R., Malladi, P. et al., Roles of phosphatidylinositol 3-kinase and osteopontin in steatosis and aminotransferase release by hepatocytes treated with methionine-choline-deficient medium. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291, G55-G62.
18. Crespo, I., García-Mediavilla, M. V., Gutiérrez, B., Sánchez-Campos, S. et al., A comparison of the effects of kaempferol and quercetin on cytokine-induced pro-inflammatory status of cultured human endothelial cells. Br. J. Nutr. 2008, 100, 968-976.
19. Dionisio, N., García-Mediavilla, M. V., Sánchez-Campos, S., Majano, P. L. et al., Hepatitis C virus NS5A and core proteins induce oxidative stress-mediated calcium signalling alterations in hepatocytes. J. Hepatol. 2009, 50, 872-882.
20. Kretzmann, N. A., Fillmann, H., Mauriz, J. L., Marroni, C. A. et al., Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis. Inflamm. Bowel Dis. 2008, 14, 1504-1513.
21. Leclercq, I. A., Farrell, G. C., Field, J., Bell, D. R. et al., CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 2000, 105, 1067-1075.
22. Ip, E., Farrell, G. C., Robertson, G., Hall, P. et al., Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003, 38, 123-132.
23. Ekstedt, M., Hagstrom, H., Nasr, P., Fredrikson, M. et al., Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2014, doi:10.1002/hep.27368.
24. Musso, G., Gambino, R., Cassader, M., Pagano, G., A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52, 79-104.
25. Almonacid-Urrego, C. C., Sánchez-Campos, S., Tuñón, M. J., González-Gallego, J., Non-alcoholic steatohepatitis: what can we learn from animal models?. Curr. Med. Chem. 2012, 19, 1389-1404.
26. Takahashi, Y., Soejima, Y., Fukusato, T., Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 2012, 18, 2300-2308.
27. Ronis, M. J., Baumgardner, J. N., Marecki, J. C., Hennings, L. et al., Dietary fat source alters hepatic gene expression profile and determines the type of liver pathology in rats overfed via total enteral nutrition. Physiol. Genomics 2012, 44, 1073-1089.
28. Jung, C. H., Cho, I., Ahn, J., Jeon, T. I. et al., Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes. Phytother. Res. 2013, 27, 139-143.
29. Zhang, L., Xu, J., Song, H., Yao, Z. et al., Extracts from Salvia-Nelumbinis naturalis alleviate hepatosteatosis via improving hepatic insulin sensitivity. J. Transl. Med. 2014, 12, 236-014-0236-8.
30. Lima-Cabello, E., García-Mediavilla, M. V., Miquilena-Colina, M. E., Vargas-Castrillón, J. et al., Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin. Sci. 2011, 120, 239-250.
31. Marcolin, E., San-Miguel, B., Vallejo, D., Tieppo, J. et al., Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. J. Nutr. 2012, 142, 1821-1828.
32. Panchal, S. K., Poudyal, H., Brown, L., Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J. Nutr. 2012, 142, 1026-1032.
33. Crespo, I., García-Mediavilla, M. V., Almar, M., González, P. et al., Differential effects of dietary flavonoids on reactive oxygen and nitrogen species generation and changes in antioxidant enzyme expression induced by proinflammatory cytokines in Chang Liver cells. Food Chem. Toxicol. 2008, 46, 1555-1569.
34. Ameer, F., Scandiuzzi, L., Hasnain, S., Kalbacher, H., Zaidi, N., De novo lipogenesis in health and disease. Metabolism 2014, 63, 895-902.
35. Chanda, D., Lee, C. H., Kim, Y. H., Noh, J. R. et al., Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. Hepatology 2009, 50, 880-892.
36. Park, H. S., Jeon, B. H., Woo, S. H., Leem, J. et al., Time-dependent changes in lipid metabolism in mice with methionine choline deficiency-induced fatty liver disease. Mol. Cells 2011, 32, 571-577.
37. Zhang, X., Shen, J., Man, K., Chu, E. S. et al., CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. J. Hepatol. 2014, 61, 1365-1375.
38. Wang, W., Wang, C., Ding, X. Q., Pan, Y. et al., Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br. J. Pharmacol. 2013, 169, 1352-1371.
39. Su, X., Abumrad, N. A., Cellular fatty acid uptake: a pathway under construction. Trends Endocrinol. Metab. 2009, 20, 72-77.
40. Eyre, N. S., Cleland, L. G., Tandon, N. N., Mayrhofer, G., Importance of the carboxyl terminus of FAT/CD36 for plasma membrane localization and function in long-chain fatty acid uptake. J. Lipid Res. 2007, 48, 528-542.
41. Wang, C., Hu, L., Zhao, L., Yang, P. et al., Inflammatory stress increases hepatic CD36 translational efficiency via activation of the mTOR signalling pathway. PLoS One 2014, 9, e103071.
42. Luo, Z. L., Tang, L. J., Wang, T., Dai, R. W. et al., Effects of treatment with hydrogen sulfide on methionine-choline deficient diet-induced non-alcoholic steatohepatitis in rats. J. Gastroenterol. Hepatol. 2014, 29, 215-222.
43. Mitsuyoshi, H., Yasui, K., Harano, Y., Endo, M. et al., Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol. Res. 2009, 39, 366-373.
44. Doege, H., Grimm, D., Falcon, A., Tsang, B. et al., Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J. Biol. Chem. 2008, 283, 22186-22192.
45. Ding, L., Liu, J. L., Hassan, W., Wang, L. L. et al., Lipid modulatory activities of Cichorium glandulosum Boiss et Huet are mediated by multiple components within hepatocytes. Sci. Rep. 2014, 4, 4715.
46. Shen, B., Yu, J., Wang, S., Chu, E. S. et al., Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. Hepatology 2008, 47, 473-483.
47. Qiao, L., Zou, C., Shao, P., Schaack, J. et al., Transcriptional regulation of fatty acid translocase/CD36 expression by CCAAT/enhancer-binding protein alpha. J. Biol. Chem. 2008, 283, 8788-8795.
48. Cabrero, A., Alegret, M., Sanchez, R. M., Adzet, T. et al., Increased reactive oxygen species production down-regulates peroxisome proliferator-activated alpha pathway in C2C12 skeletal muscle cells. J. Biol. Chem. 2002, 277, 10100-10107.
49. Motojima, K., Passilly, P., Peters, J. M., Gonzalez, F. J. et al., Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J. Biol. Chem. 1998, 273, 16710-16714.
50. Huang, J., Iqbal, J., Saha, P. K., Liu, J. et al., Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology 2007, 46, 147-157.
51. Bechmann, L. P., Kocabayoglu, P., Sowa, J. P., Sydor, S. et al., Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013, 57, 1394-1406.
52. Yang, C. S., Yuk, J. M., Kim, J. J., Hwang, J. H. et al., Small heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2. PLoS One 2013, 8, e63435.
53. Trauner, M., A little orphan runs to fat: the orphan receptor small heterodimer partner as a key player in the regulation of hepatic lipid metabolism. Hepatology 2007, 46, 1-5.
54. Del Bas, J. M., Ricketts, M. L., Baiges, I., Quesada, H. et al., Dietary procyanidins lower triglyceride levels signaling through the nuclear receptor small heterodimer partner. Mol. Nutr. Food Res. 2008, 52, 1172-1181.
55. García-Mediavilla, M. V., Pisonero-Vaquero, S., Lima-Cabello, E., Benedicto, I. et al., Liver X receptor alpha-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication. Lab. Invest. 2012, 92, 1191-1202.
56. Xu, D., Huang, X. D., Yuan, J. P., Wu, J. et al., Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD. Hepatogastroenterology 2011, 58, 1703-1707.
57. Kim, S. M., Jang, H., Son, Y., Lee, S. A. et al., 27-hydroxycholesterol induces production of tumor necrosis factor-alpha from macrophages. Biochem. Biophys. Res. Commun. 2013, 430, 454-459.
58. Rios, F. J., Koga, M. M., Ferracini, M., Jancar, S., Co-stimulation of PAFR and CD36 is required for oxLDL-induced human macrophages activation. PLoS One 2012, 7, e36632.
59. Datta, J., Majumder, S., Kutay, H., Motiwala, T. et al., Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res. 2007, 67, 2736-2746.
60. Vivanco, I., Sawyers, C. L., The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489-501.
61. Wang, G. L., Iakova, P., Wilde, M., Awad, S. et al., Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity. Genes Dev. 2004, 18, 912-925.
62. Kim, H. S., Park, E. J., Park, S. W., Kim, H. J. et al., A tetrahydroisoquinoline alkaloid THI-28 reduces LPS-induced HMGB1 and diminishes organ injury in septic mice through p38 and PI3K/Nrf2/HO-1 signals. Int. Immunopharmacol. 2013, 17, 684-692.
63. Kwak, D. H., Lee, J. H., Song, K. H., Ma, J. Y., Inhibitory effects of baicalin in the early stage of 3T3-L1 preadipocytes differentiation by down-regulation of PDK1/Akt phosphorylation. Mol. Cell. Biochem. 2014, 385, 257-264.
64. Bumke-Vogt, C., Osterhoff, M. A., Borchert, A., Guzman-Perez, V. et al., The flavones apigenin and luteolin induce FOXO1 translocation but inhibit gluconeogenic and lipogenic gene expression in human cells. PLoS One 2014, 9, e104321.
65. Luiken, J. J., Koonen, D. P., Willems, J., Zorzano, A. et al., Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 2002, 51, 3113-3119.
66. Huang, J., Tabbi-Anneni, I., Gunda, V., Wang, L., Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299, G1211-G1221.
67. Waris, G., Felmlee, D. J., Negro, F., Siddiqui, A., Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J. Virol. 2007, 81, 8122-8130.